Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.58 |
| ▸ | MAOB | P27338 | 16/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30966001 | 0.92 | GRM5 (0.53) | GRM5MAOBNPC1ALDH1A1HPGD | |
| SCHEMBL30966000 | 0.89 | GRM5 (0.50) | GRM5MAOBNPC1ALDH1A1HPGD | |
| SCHEMBL12316591 | 0.88 | GRM5 (0.45) | GRM5MAOBNPC1ALDH1A1HPGD | |
| SCHEMBL13506182 | 0.81 | MAOB (0.63) | GRM5MAOBNPC1ALDH1A1HPGD | |
| SCHEMBL551972 | 0.81 | MAOB (0.55) | GRM5MAOBNPC1ALDH1A1HPGD | |
| SCHEMBL20554219 | 0.80 | MAOB (0.52) | GRM5MAOBNPC1ALDH1A1HPGD | |
| SCHEMBL30132637 | 0.80 | MAOB (0.52) | GRM5MAOBNPC1ALDH1A1HPGD | |
| SCHEMBL14481253 | 0.80 | KCNH2 (0.54) | GRM5MAOBNPC1ALDH1A1HPGD | |
| SCHEMBL67621 | 0.80 | MAOB (0.60) | GRM5MAOBNPC1ALDH1A1HPGD | |
| Cyclopropane SCHEMBL28516873 | 0.78 | MAOB (0.59) | GRM5MAOBNPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130029978-A1 | NOVEL ARYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. | 2013-01-31 | — | — | US | disclosed |
| EP-2518064-A1 | NOVEL ARYL UREA DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029978-A1 | NOVEL ARYL UREA DERIVATIVE | FAAH, FAAH2, NAT1 | GRM5 4254/4885MAOB 226/4885NPC1 1706/4885 |
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | GRM5 200/4885MAOB 990/4885NPC1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.